Fred A. Wininger

Fred A. Wininger

Auto-generated profile, based on publicly available information

Fred A. Wininger

Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2010 in Veterinary Clinics of North America: Small Animal Practice
Verified
Journal Article
Closed access
JCJoan Ripley Coates
Joan Ripley Coates
FWFred A. Wininger
Fred A. Wininger

1 June 2011 in Neurobiology of Disease
Verified
Journal Article
Closed access
FFFabiana H.G. Farias
Fabiana H.G. Farias
RZRong Zeng
Rong Zeng
GJGary S. Johnson
Gary S. Johnson
FWFred A. Wininger
Fred A. Wininger
JTJeremy F. Taylor
Jeremy F. Taylor
MKMartin L. Katz
Martin L. Katz

17 June 2014 in Journal of Neuroscience Research
Verified
Journal Article
Open access
PDF file
MKMartin L. Katz
Martin L. Katz
JCJoan R. Coates
Joan R. Coates
CSChristine M. Sibigtroth
Christine M. Sibigtroth
JTJacob D. Taylor
Jacob D. Taylor
MCMelissa Carpentier
Melissa Carpentier
COCharles A. O'NEill
Charles A. O'NEill
Using a canine model of classical late‐infantile neuronal ceroid lipofuscinosis (CLN2 disease), a study was conducted to evaluate the potential pharmacological activity of recombinant human tripeptidyl peptidase‐1 (rhTPP1) enzyme replacement therapy administered directly to the cerebrospinal fluid (CSF). CLN2 disease is a hereditary neurodegenerative disorder resulting from mutations in CLN2, which encodes the soluble lysosomal enzyme tripeptidyl peptidase‐1 (TPP1). Infants with mutations in both CLN2 alleles develop normally but in the late‐infantile/early‐childhood period undergo progressive neurological decline accompanied by pronounced brain atrophy. The disorder, a form of Batten disease, is uniformly fatal, with clinical signs starting between 2 and 4 years of age and death usually occurring by the early teenage years. Dachshunds homozygous for a null mutation in the canine ortholog of CLN2 (TPP1) exhibit a similar disorder that progresses to end stage at 10.5–11 months of age. Administration of rhTPP1 via infusion into the CSF every other week, starting at approximately 2.5 months of age, resulted in dose‐dependent significant delays in disease progression, as measured by delayed onset of neurologic deficits, improved performance on a cognitive function test, reduced brain atrophy, and increased life span. Based on these findings, a clinical study evaluating the potential therapeutic value of rhTPP1 administration into the CSF of children with CLN2 disease has been initiated. © 2014 The Authors. Journal of Neuroscience Research Published by Wiley Periodicals, Inc.

28 November 2011 in Veterinary Radiology & Ultrasound
Verified
Journal Article
Closed access
PDF file
ACAnnie V. Chen
Annie V. Chen
FWFred A. Wininger
Fred A. Wininger
SFStephen Frey
Stephen Frey
RCRoch M. Comeau
Roch M. Comeau
RBRodney S. Bagley
Rodney S. Bagley
JGJohn M. Gay
John M. Gay

16 August 2011 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
PDF file
FWF.A. Wininger
F.A. Wininger
RZR. Zeng
R. Zeng
GJG.S. Johnson
G.S. Johnson
MKM.L. Katz
M.L. Katz
GJG.C. Johnson
G.C. Johnson
JCJ.R. Coates
J.R. Coates

26 November 2013 in Veterinary Pathology
Verified
Journal Article
Open access
GJGayle Johnson
Gayle Johnson
JCJ. R. Coates
J. R. Coates
FWF. Wininger
F. Wininger
The focus of immunohistochemistry as applied to nervous system tumors is in identifying the neoplasm present and evaluating margins between normal and neoplastic tissue. Although not always utilized by specialists in neuropathology, immunohistochemistry remains useful to resolve concerns about the differentiation and rate of tumor growth. The aims of this review are to discuss the utility of immunohistochemical reagents currently used in diagnosis of canine and feline intracalvarial tumors, to indicate the applicability of some tests currently used in human nervous system tumors for domestic species, and to evaluate a few less commonly used reagents. A panel of biomarkers is usually needed to confirm a diagnosis, with groups of reagents for leptomeningeal, intraparenchymal, and ventricular neoplasms. In the future, signature genetic alterations found among feline and canine brain tumors—as correlated prospectively with diagnosis, rate of enlargement, or response to treatment—may result in new immunohistochemical reagents to simplify the task of diagnosis. Prospective studies determining the type and proportion of stem cell marker expression on patient longevity are likely to be fruitful and suggest new therapies. Due to increased frequency of biopsy or partial resection of tumors from the living patient, biomarkers are needed to serve as accurate prognostic indicators and assist in determining the efficacy of developing therapeutic options in nervous system tumors of dogs and cats.